Related Experiment Videos
Antitumor and antimetastatic activities of human recombinant interferon alpha A/D
Abstract:
Human recombinant interferon alpha A/D (alpha A/D) was examined for its antitumor activity in several mouse tumor models using metastatic tumors, such as B16 melanoma F1, BL6 and F10, UV2237m fibrosarcoma, and K1735m melanoma. Therapeutic treatment with alpha A/D reduced the incidence of pulmonary metastasis and inhibited the tumor growth resulting in an increase of the mean survival time. Since alpha A/D also showed a prophylactic activity against the metastasis, its antitumor activity was suggested to be due to augmentation of the host defense systems. This was confirmed by the fact that alpha A/D inhibited the in vivo growth and incidence of pulmonary metastasis of B16 F1 sublines regardless of their sensitivity to the direct antiproliferative activity of the IFN in vitro.
Insights
Human recombinant interferon alpha A/D demonstrated significant antitumor effects against metastatic mouse tumors. This interferon therapy reduced metastasis, inhibited tumor growth, and improved survival by enhancing host defense systems.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Metastatic tumors pose a significant challenge in cancer treatment.
- Interferons are known for their immunomodulatory and antiproliferative properties.
- Understanding the mechanisms of antitumor activity is crucial for therapeutic development.
Purpose of the Study:
- To evaluate the antitumor activity of human recombinant interferon alpha A/D (alpha A/D) in various mouse metastatic tumor models.
- To investigate the prophylactic and therapeutic effects of alpha A/D on metastasis.
- To determine if the antitumor activity is mediated by host defense system augmentation.
Main Methods:
- Testing alpha A/D in mouse models including B16 melanoma, UV2237m fibrosarcoma, and K1735m melanoma.
- Assessing the incidence of pulmonary metastasis and tumor growth inhibition.
- Evaluating the in vivo and in vitro antiproliferative activity of alpha A/D.
Main Results:
- Therapeutic treatment with alpha A/D reduced pulmonary metastasis incidence and inhibited tumor growth.
- Alpha A/D treatment led to an increased mean survival time in tumor-bearing mice.
- Prophylactic administration of alpha A/D also showed activity against metastasis.
- The antitumor effect was observed even in tumor sublines insensitive to direct antiproliferative activity of interferon in vitro, suggesting host defense modulation.
Conclusions:
- Human recombinant interferon alpha A/D exhibits potent antitumor and antimetastatic activity in preclinical mouse models.
- The therapeutic efficacy of alpha A/D appears to be mediated through the augmentation of host defense mechanisms.
- Interferon alpha A/D represents a promising therapeutic agent for managing metastatic cancers.